Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain

Nanotechnology

Volumn 23, Issue 16, 2012, Pages

  Lin, Yong ^a   Pan, Yaohua ^a   Shi, Yinfeng ^b   Huang, Xianjian ^a   Jia, Nengqin ^b   Jiang, Ji Yao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD-BRAIN BARRIER; BUTYL CYANOACRYLATE; CENTRAL NERVOUS SYSTEMS; CIRCULATION TIME; DELIVERY SYSTEMS; DISPERSION POLYMERIZATION; ENHANCED GREEN FLUORESCENT PROTEIN; HORSE-RADISH PEROXIDASE; IMMUNOLOCALIZATION; POLYSORBATE 80; POLYSORBATES; RAT BRAIN; SMALL-MOLECULE DRUGS; TRAUMATIC BRAIN INJURIES;

BIOSYNTHESIS; BRAIN; MOLECULES; RATS;

NANOPARTICLES;

ENBUCRILATE; MULTIPROTEIN COMPLEX; NANOCAPSULE;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INJURY; CHEMISTRY; DIFFUSION; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN INJURIES; DIFFUSION; ENBUCRILATE; MALE; MULTIPROTEIN COMPLEXES; NANOCAPSULES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84859359362     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/16/165101     Document Type: Article

References (44)

1. Wolburg H and Lippoldt A 2002 Tight junctions of the bloodbrain barrier: development, composition and regulation Vasc. Pharmacol. 38 32337 (Pubitemid 36398254)
2. Hawkins B T and Davis T P 2005 The bloodbrain barrier/neurovascular unit in health and disease Pharmacol. Rev. 57 17385 (Pubitemid 41043883)
3. Abbott N J, Rönnbäck L and Hansson E 2006 Astrocyteendothelial interactions at the bloodbrain barrier Nature Rev. Neurosci. 7 4153
4. de Boer A G and Gaillard P J 2007 Drug targeting to the brain Annu. Rev. Pharmacol. Toxicol. 47 32355
5. Jain K K 2007 Nanobiotechnology-based drug delivery to the central nervous system Neurodegener. Dis. 4 28791 (Pubitemid 47026182)
6. Gilmore J L, Yi X, Quan L and Kabanov A V 2008 Novel nanomaterials for clinical neuroscience J. Neuroimmune Pharmacol. 3 8394
7. Neuwelt E A, Maravilla K R, Frenkel E P, Rapaport S I, Hill S A and Barnett P A 1979 Osmotic bloodbrain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery J. Clin. Invest. 64 6848 (Pubitemid 9237606)
8. Gumerlock M K, Belshe B D, Madsen R and Watts C 1992 Osmotic bloodbrain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review J. Neurooncol. 12 3346
9. Kroll R A and Neuwelt E A 1998 Outwitting the bloodbrain barrier for therapeutic purposes: osmotic opening and other means Neurosurgery 42 1083100 (Pubitemid 28196521)
10. Brown R C, Egleton R D and Davis T P 2004 Mannitol opening of the bloodbrain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin Brain Res. 1014 2217 (Pubitemid 38798466)
11. Ghajar J 2000 Traumatic brain injury Lancet 356 9239
12. Werner C and Engelhard K 2007 Pathophysiology of traumatic brain injury Br. J. Anaesth. 99 49 (Pubitemid 47072553)
13. Dixon C E, Flinn P, Bao J, Venya R and Hayes R L 1997 Nerve growth factor attenuates cholinergic deficits following traumatic brain injury in rats Exp. Neurol. 146 47990 (Pubitemid 27381855)
14. Duvdevani R, Roof R L, Fulop Z, Hoffman S W and Stein D G 1995 Bloodbrain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role? J. Neurotrauma 12 6575
15. Adelson P D, Whalen M J, Kochanek P M, Robichaud P and Carlos T M 1998 Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report Acta Neurochir. Suppl. 71 1046 (Pubitemid 128444370)
16. Shigemori Y, Katayama Y, Mori T, Maeda T and Kawamata T 2006 Matrix metalloproteinase-9 is associated with bloodbrain barrier opening and brain edema formation after cortical contusion in rats Acta Neurochir. Suppl. 96 1303
17. Habgood M D, Bye N, Dziegielewska K M, Ek C J, Lane M A, Potter A, Morganti-Kossmann C and Saunders N R 2007 Changes in bloodbrain barrier permeability to large and small molecules following traumatic brain injury in mice Eur. J. Neurosci. 25 2318 (Pubitemid 46096237)
18. Beaumont A, Marmarou A, Hayasaki K, Barzó P, Fatouros P, Corwin F, Marmarou C and Dunbar J 2000 The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury Acta Neurochir. Suppl. 76 1259
19. Schneider G, Fries P, Wagner-Jochem D, Thome D, Laurer H, Kramann B, Mautes A and Hagen T 2002 Pathophysiological changes after traumatic brain injury: comparison of two experimental animal models by means of MRI MAGMA 14 23341 (Pubitemid 34786974)
20. Alyautdin R, Gothier D, Petrov V, Kharkevich D and Kreuter J 1995 Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80coated poly(butyl cyanoacrylate) nanoparticles Eur. J. Pharm. Biopharm. 41 448
21. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R and Betbeder D 1999 Evaluation of effect of charge and lipid coating on ability of 60 nm nanoparticles to cross an in vitro model of the bloodbrain barrier J. Pharmacol. Exp. Ther. 291 101722
22. Olivier J C, Fenart L, Chauvet R, Pariat C, Cecchelli R and Couet W 1999 Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity Pharm. Res. 16 183642 (Pubitemid 30040699)
23. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina S E, Engelhardt B, Alyautdin R, von Briesen H and Begley D J 2003 Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 40916 (Pubitemid 36288370)
24. Taira S, Moritake S, Hatanaka T, Ichiyanagi Y and Setou M 2009 Functionalized magnetic nanoparticles as an in vivo delivery system Methods Mol. Biol. 544 57187
25. Soehendra N, Grimm H, Nam V C and Berger B 1987 N-butyl-2-cyanoacrylate: a supplement to endoscopic sclerotherapy Endoscopy 19 2214 (Pubitemid 18016292)
26. Amiel G E, Sukhotnik I, Kawar B and Siplovich L 1999 Use of N-butyl-2-cyanoacrylate in elective surgical incisionslongterm outcomes J. Am. Coll. Surg. 189 215 (Pubitemid 29307738)
27. Jafar J J, Davis A J, Berenstein A, Choi I S and Kupersmith M J 1993 The effect of embolization with N-butyl cyanoacrylate prior to surgical resection of cerebral arteriovenous malformations J. Neurosurg. 78 609 (Pubitemid 23005354)
28. Mazal P R, Stichenwirth M, Gruber A, Sulzbacher I and Hainfellner J A 2006 Tissue reactions induced by different embolising agents in cerebral arteriovenous malformations: a histopathological follow-up Pathology 38 2832 (Pubitemid 43259248)
29. Starke R M et al 2009 Adjuvant embolization with N-butyl cyanoacrylate in the treatment of cerebral arteriovenous malformations: outcomes, complications, and predictors of neurologic deficits Stroke 40 278390
30. Behan N, Birkinshaw C and Clarke N 2001 Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation Biomaterials 22 133544 (Pubitemid 32409955)
31. Alyautdin R N, Petrov V E, Langer K, Berthold A, Kharkevich D A and Kreuter J 1997 Delivery of loperamide across the bloodbrain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles Pharm. Res. 14 3258 (Pubitemid 27160944)
32. Gulyaev A E, Gelperina S E, Skidan I N, Antropov A S, Kivman G Y and Kreuter J 1999 Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles Pharm. Res. 16 15649 (Pubitemid 29510553)
33. Reukov V, Maximov V and Vertegel A 2011 Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents Biotechnol. Bioeng. 108 24352
34. McIntosh T K, Vink R, Noble L, Yamakami I, Fernyak S, Soares H and Faden A L 1989 Traumatic brain injury in the rat: characterization of a lateral fluid-percussion model Neuroscience 28 23344 (Pubitemid 19026758)
35. Desai M P, Labhasetwar V, Walter E, Levy R J and Amidon G L 1997 The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent Pharm. Res. 14 156873 (Pubitemid 28009208)
36. Panyam J and Labhasetwar V 2003 Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv. Drug Deliv. Rev. 55 32947 (Pubitemid 36297053)
37. Lockman P, Mumper R J, Khan M A and AllenD D 2002 Nanoparticle technology for drug delivery across the blood brain barrier Drug Dev. Indust. Pharm. 28 113 (Pubitemid 34279373)
38. Suri S S, Fenniri H and Singh B 2007 Nanotechnology-based drug delivery systems J. Occup. Med. Toxicol. 2 16
39. de Jong W H and Borm P J 2008 Drug delivery and nanoparticles: applications and hazards Int. J. Nanomed. 3 13349 (Pubitemid 352042401)
40. Gupta R B 2006 Fundamentals of drug nanoparticles Nanoparticle Technology for Drug Delivery ed R B Gupta and U B Kompella (New York: Taylor and Francis) pp 119
41. Reimold I, Domke D, Bender J, Seyfried C A, Radunz H E and Fricker G 2008 Delivery of nanoparticles to the brain detected by fluorescence microscopy Eur. J. Pharm. Biopharm. 70 62732
42. Koffie R M, Farrar C T, Saidi L J, William C M, Hyman B T and Spires-Jones T L 2011 Nanoparticles enhance brain delivery of bloodbrain barrier-impermeable probes for in vivo optical and magnetic resonance imaging Proc. Natl Acad. Sci. USA 108 1883742
43. Lotocki G, Rivero Vaccari J P, Perez E R, Sanchez-Molano J, Furones-Alonso O, Bramlett H M and Dietrich W D 2009 Alterations in bloodbrain barrier permeability to large and small molecules and leukocyte accumulation after traumatic brain injury: effects of post-traumatic hypothermia J. Neurotrauma 26 112334
44. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C and Alyautdin R 2002 Apolipoprotein-mediated transport of nanoparticle-bound drugs across the bloodbrain barrier J. Drug Target 10 31725 (Pubitemid 34746313)